Authors:
Buter, H
Navis, G
Dullaart, RPF
de Zeeuw, D
de Jong, PE
Citation: H. Buter et al., Time course of the antiproteinuric and renal haemodynamic responses to losartan in microalbuminuric IDDM, NEPH DIAL T, 16(4), 2001, pp. 771-775
Authors:
Laverman, GD
Henning, RH
de Jong, PE
Navis, G
de Zeeuw, D
Citation: Gd. Laverman et al., Optimal antiproteinuric dose of losartan in nondiabetic patients with nephrotic range proteinuria, AM J KIDNEY, 38(6), 2001, pp. 1381-1384
Authors:
Boonstra, A
de Zeeuw, D
de Jong, PE
Navis, G
Citation: A. Boonstra et al., Role of genetic variability in the renin-angiotensin system in diabetic and nondiabetic renal disease, SEM NEPHROL, 21(6), 2001, pp. 580-592
Authors:
Smit-van Oosten, A
Navis, G
Stegeman, CA
Joles, JA
Klok, PA
Kuipers, F
Tiebosch, ATMG
van Goor, H
Citation: A. Smit-van Oosten et al., Chronic blockade of angiotensin II action prevents glomerulosclerosis, butinduces graft vasculopathy in experimental kidney transplantation, J PATHOLOGY, 194(1), 2001, pp. 122-129
Authors:
Wapstra, FH
Navis, G
De Jong, PE
De Zeeuw, D
Citation: Fh. Wapstra et al., Chronic angiotensin II infusion but not bradykinin blockade abolishes the antiproteinuric response to angiotensin-converting enzyme inhibition in established adriamycin nephrosis, J AM S NEPH, 11(3), 2000, pp. 490-496
Authors:
Pinto-Sietsma, SJ
Janssen, WMT
Hillege, HL
Navis, G
De Zeeuw, D
De Jong, PE
Citation: Sj. Pinto-sietsma et al., Urinary albumin excretion is associated with renal functional abnormalities in a nondiabetic population, J AM S NEPH, 11(10), 2000, pp. 1882-1888
Authors:
van Paassen, P
de Zeeuw, D
Navis, G
de Jong, PE
Citation: P. Van Paassen et al., Renal and systemic effects of continued treatment with renin inhibitor remikiren in hypertensive patients with normal and impaired renal function, NEPH DIAL T, 15(5), 2000, pp. 637-643
Authors:
Bos, H
Andersen, S
Rossing, P
de Zeeuw, D
Parving, HH
de Jong, PE
Navis, G
Citation: H. Bos et al., Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy, KIDNEY INT, 57, 2000, pp. S32-S37
Authors:
Wapstra, FH
van Goor, H
de Jong, PE
Navis, G
de Zeeuw, D
Citation: Fh. Wapstra et al., Dose of doxorubicin determines severity of renal damage and responsivenessto ACE-inhibition in experimental nephrosis, J PHARM TOX, 41(2-3), 1999, pp. 69-73
Authors:
De Boer, E
Navis, G
Tiebosch, ATM
De Jong, PE
De Zeeuw, D
Citation: E. De Boer et al., Systemic factors are involved in the pathogenesis of proteinuria-induced glomerulosclerosis in adriamycin nephrotic rats, J AM S NEPH, 10(11), 1999, pp. 2359-2366
Authors:
Broekroelofs, J
Stegeman, CA
Navis, G
de Jong, PE
Citation: J. Broekroelofs et al., Prevention of renal function loss after non-renal solid organ transplantation - how can nephrologists help to keep the kidneys out of the line of fire?, NEPH DIAL T, 14(8), 1999, pp. 1841-1843
Authors:
de Vries, PAM
Navis, G
de Jong, PE
de Zeeuw, D
Citation: Pam. De Vries et al., Impaired renal vascular response to a D-1-like receptor agonist but not toan ACE inhibitor in conscious spontaneously hypertensive rats, J CARDIO PH, 34(2), 1999, pp. 191-198
Authors:
de Boer, E
Navis, G
Wapstra, FH
de Jong, PE
de Zeeuw, D
Citation: E. De Boer et al., Effect of proteinuria reduction on prevention of focal glomerulosclerosis by angiotensin-converting enzyme inhibition is modifiable, KIDNEY INT, 56, 1999, pp. S42-S46